astrazeneca glp 1 drug AstraZeneca’s experimental obesity pill helped patients lose up to 11.8% of their body weight in a mid-stage trial, as competition intensifies in the rapidly growing market for oral weight-loss drugs. 2025’s Breakthrough GLP-1 Obesity Treatments:

These medications help: Slow stomach emptying, leading to increased feelings of fullness Reduce appetite and food intake by acting on brain centers that control hunger Improve insulin secretion and sensitivity Lower blood sugar levels, especially after meals Promote weight loss through multiple mechanisms Mounjaro (tirzepatide) is actually a dual GIP/GLP-1 receptor agonist, meaning it acts on two hormonal pathways related to blood sugar control and appetite regulation, which may explain its particularly strong effects on weight loss

This matters because a diverse, balanced microbiome tends to produce less hydrogen sulfide than one dominated by sulfate-reducing bacteria

Significantly so

All work was approved by the Institutional Animal Care and Use Committee (IACUC

As for the veggies , consider kale, collards, brussels sprouts, carrots, cabbage, and kidney beans